Dimitrios Chondros Form 3 HALOZYME THERAPEUTICS / Dimitrios Chondros ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Chondros Dimitrios

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

11388 SORRENTO VALLEY ROAD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/02/2018

3. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS INC [ HALO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
SVP, Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	34,076(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	08/03/2016(2)	08/03/2025	Common Stock	100,000	23.03	D
Option to Purchase Common Stock	02/03/2017(2)	02/03/2026	Common Stock	41,841	8.11	D
Option to Purchase Common Stock	02/22/2018(2)	02/22/2027	Common Stock	24,861	12.07	D
Option to Purchase Common Stock	06/01/2018(3)	06/01/2027	Common Stock	13,218	12.24	D
Option to Purchase Common Stock	02/14/2019(3)	02/14/2028	Common Stock	47,635	18.41	D
Restricted Stock Units	02/22/2018(4)	(4)	Common Stock	11,651	(4)	D
Restricted Stock Units	02/14/2019(5)	(5)	Common Stock	8,170	(5)	D
Restricted Stock Units	02/14/2019(5)	(5)	Common Stock	27,160	(5)	D

Explanation of Responses:

1. Includes 7,500 shares of restricted stock that vest in equal pro rata amounts on August 3, 2018 and August 3, 2019. Also includes 12,330 shares of restricted stock that vest in equal pro rata amounts on February 3, 2019 and February 3, 2020.

2. This option vested one-fourth on such date and vests 1/48th monthly thereafter.

3. This option vests one-fourth on such date and then 1/48th monthly thereafter.

4. This award vested one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Represents a restricted stock unit award with no exercise price.

5. This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Represents a restricted stock unit award with no exercise price.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ James R. Oehler as attorney-in-fact for Dimitrios Chondros	05/07/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.